861340-10-5

Basic information

• Product Name: 1H-indazole-4-carbonitrile
• Synonyms: 1H-indazole-4-carbonitrile;4-CYANO (1H)INDAZOLE;4-Indazolenitrile
• CAS NO: 861340-10-5
• Molecular Formula: C₈H₅N₃
• Molecular Weight: 143.14
• Product Categories: Building Blocks;Indazole
• Mol File: 861340-10-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 157-160 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 370.3 °C at 760 mmHg
• Flash Point: 126.7 °C
• Appearance: /
• Density: 1.33 g/cm³
• Vapor Pressure: 1.12E-05mmHg at 25°C
• Refractive Index: 1.684
• Storage Temp.: 2-8°C(protect from light)
• PKA: 11.61±0.40(Predicted)
• CAS DataBase Reference: 1H-indazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-indazole-4-carbonitrile(861340-10-5)
• EPA Substance Registry System: 1H-indazole-4-carbonitrile(861340-10-5)

Safety Data

• Hazardous Substances Data: 861340-10-5(Hazardous Substances Data)

Usage

General Description

1H-Indazole-4-carbonitrile is a chemical compound with the molecular formula C8H6N4. It is a member of the indazole family and contains a carbonitrile functional group. 1H-Indazole-4-carbonitrile is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and chemical properties make it a valuable intermediate in the production of a wide range of organic compounds. 1H-Indazole-4-carbonitrile has potential applications in the fields of medicinal chemistry and material science, and its versatile nature makes it a valuable tool for chemical research and development.

InChI:InChI=1/C8H5N3/c9-4-6-2-1-3-8-7(6)5-10-11-8/h1-3,5H,(H,10,11)

Upstream product

• 557-21-1 zinc(II) cyanide 
• 186407-74-9 4-bromoindazole 
• 557-21-1 dicyanozinc 

Downstream Products

• 871351-37-0 1-(3-chloro-1-phenyl-propyl)-1H-indazole-4-carbonitrile 
• 1312008-98-2 4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazole 
• 1312008-97-1 methyl 3-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]-2-methylpropanoate 
• 1312008-99-3 methyl 5-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]pentanoate 
• 1312009-00-9 methyl 5-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2H-indazol-2-yl]pentanoate 
• 1312009-01-0 ethyl {3-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]-3-oxetanyl}acetate 
• 1312009-30-5 5-[3-(1H-indazol-4-yl)-1,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile 
• 1312009-32-7 3-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]-2-methylpropanoic acid 
• 1312009-34-9 5-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]pentanoic acid 
• 1312009-36-1 5-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2H-indazol-2-yl]pentanoic acid 
• 1312009-37-2 {3-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]-3-oxetanyl}acetic acid 
• 1159511-45-1 2-methyl-2H-indazole 4-carbonitrile 
• 944898-93-5 3-iodo-1H-indazole-4-carbonitrile 

Relevant articles and documents

OXADIAZOLE DERIVATIVES AND PHARMACEUTICAL USES THEREOF

PROBLEM TO BE SOLVED: To provide therapeutic or preventive agents for various diseases or symptoms associated with a serotonin 4 receptor (particularly, neuropsychiatric diseases such as Alzheimer-type dementia). SOLUTION: The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. In the formula (1), Het represents formula (Het-1) or the like, A represents formula (A-1) or the like, B represents (B-1) or the like, R1A represents a hydrogen atom, an alkyl group or the like, R2A, R5, R6 and R7 represent a hydrogen atom, a halogen atom, an alkyl group or the like, R8 and R9 represent a hydrogen atom, an alkyl group or the like, and l represents an integer of 0-4. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR

Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein, pharmaceutical compositions containing them and methods of using them for the preparation of medicaments for treating depression or anxiety.